Figure 6.
PeptiCRAd, in combination with anti-PD1, improves tumor growth control and survival compared to either monotherapy and triggers a systemic anti-tumor memory response in a syngeneic mouse model of B16.F10.9/K1
(A) Anti-PD-1 immune checkpoint inhibitor alone (200 μg/dose given intraperitoneally), 1 × 109 VP of PeptiCRAd VALO-mD901-Trp2 alone, or in combination with anti-PD-1 immune checkpoint inhibitor were given intratumorally 9, 10, 11, 12, 13, and 26 days post-tumor implantation. Average tumor growth curves for all treatment groups are shown. (B) Kaplan-Meier survival curve for all treatment groups. (C) Individual tumor volumes for rechallenged mice at day 29 after secondary tumor engraftment. The numbers of mice in each group were 8−9 in (A) and (B) and 3−5 in (C). Statistical analysis was performed with two-way ANOVA for (A) and with log-rank test for (B). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001.